Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | CES2 | O00748 | 4/20 | 0.40 |
| ▸ | CES1 | P23141 | 4/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11388609 | 0.83 | ALDH1A1 (0.50) | ALDH1A1ALOX15CES2CES1MAPT | |
| SCHEMBL27514049 | 0.82 | ALDH1A1 (0.48) | ALDH1A1ALOX15CES2CES1PRMT5 | |
| SCHEMBL30281127 | 0.80 | ALDH1A1 (0.56) | ALDH1A1ALOX15MAPTHDAC8GAA | |
| SCHEMBL465752 | 0.80 | ALDH1A1 (0.56) | ALDH1A1ALOX15MAPTHDAC8GAA | |
| SCHEMBL4667818 | 0.80 | ALDH1A1 (0.50) | ALDH1A1ALOX15CES2CES1MAPT | |
| SCHEMBL2153533 | 0.80 | ALDH1A1 (0.50) | ALDH1A1ALOX15KMT2ATDP1HPGD | |
| SCHEMBL25209513 | 0.79 | CTSD (0.50) | ALDH1A1PRMT5MAPTGAAKMT2A | |
| SCHEMBL4891168 | 0.79 | ALDH1A1 (0.46) | ALDH1A1ALOX15CES2CES1MAPT | |
| SCHEMBL4318041 | 0.78 | ALDH1A1 (0.48) | ALDH1A1ALOX15CES2CES1MAPT | |
| SCHEMBL14523913 | 0.78 | LMNA (0.43) | ALDH1A1ALOX15CES2CES1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
| US-9957271-B2 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957271-B2 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3148975-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| EP-2768509-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2768509-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9326986-B2 | Quinazolinone, quinolone and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2016-05-03 | — | — | US | disclosed |
| US-9326986-B2 | Quinazolinone, quinolone and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2016-05-03 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| EP-2344475-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010037129-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010037129-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20070082877-A1 | Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof | BAYER CORPSCIENCE AKTIENGESELLSCHAFT (DE) | 2007-04-12 | — | — | US | disclosed |
| US-20070082877-A1 | Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof | BAYER CORPSCIENCE AKTIENGESELLSCHAFT (DE) | 2007-04-12 | — | — | US | disclosed |
| US-20070082877-A1 | Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof | BAYER CORPSCIENCE AKTIENGESELLSCHAFT (DE) | 2007-04-12 | — | — | US | disclosed |
| CN-1791569-A | Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof | BAYER CROPSCIENCE AG (DE) | 2006-06-21 | — | — | CN | disclosed |
| EP-1628948-A1 | DIFLUOROMETHYLBENZANILIDES AND USE THEREOF FOR COMBATING MICRO-ORGANISMS, INTERMEDIATE PRODUCTS AND USE THEREOF | Bayer CropScience AG (DE) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004103953-A1 | DIFLUOROMETHYLBENZANILIDES AND USE THEREOF FOR COMBATING MICRO-ORGANISMS, INTERMEDIATE PRODUCTS AND USE THEREOF | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | ALDH1A1 1976/4885ALOX15 1277/4885CES2 4052/4885 |
| US-20070082877-A1 | Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof | FBL, Q6ZSR9, DDT | ALDH1A1 380/4885ALOX15 3082/4885CES2 1715/4885 |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ALDH1A1 1480/4885ALOX15 1393/4885CES2 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.